Table 5 Phase II 1981–1990: Exploration of natural cyclodextrins and emergence of its derivatives for drug delivery
From: Chronicle updates in cyclodextrin-based carriers for drug delivery
Sr. No. | Year | CD type/ derivative | Drug | Class of drug | system/model | Problem of drug delivery/ result | Reference |
|---|---|---|---|---|---|---|---|
1 | 1981 | γ –CD | Digoxin | Cardiac glycoside | In vivo (dog) | Variable bioavailability, toxicity | Uekama et al. 1981a) |
2 | 1981 | β-CD | Indomethacin | Anti-inflammatory | In vivo (rat) | Bioavailability | Szejtli and Szente (1981) |
3 | 1981 | β-CD | Barbiturates | Hypnotic agent | Sleeping time studies in mice | Solubility thus bioavailability | IwAoKu et al. (1982) |
4 | 1981 | α-, β- and γ-CD | Chlorpromazine | Anti-psychotic | In vitro and in vivo rats | Reduced haemolysis with no reduction in central nervous system effect | Uekama et al. (1981b) |
5 | 1982 | β-CD | Phenobarbital | Anti-convulsant | Rectal delivery in mice | Required rapid release and absorption in child | IwAoKu et al. (1982) |
6 | 1982 | tri-o-methyl-β- CD | Flurbiprofen | Anti-inflammatory | Oral delivery to rabbits | Bioavailability studies of tri-o-methyl-β-CD/ 5 times early and 3 times higher Cmax was achieved | Otagiri et al. (1982) |